<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39401962</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>14</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Cohort profile: an observational population-based cohort study on COVID-19 vaccine effectiveness in the Netherlands - the VAccine Study COVID-19 (VASCO).</ArticleTitle><Pagination><StartPage>e085388</StartPage><MedlinePgn>e085388</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e085388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2024-085388</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">VAccine Study COVID-19 (VASCO) is a cohort study with a 5-year follow-up that was initiated when COVID-19 vaccination was introduced in the Netherlands. The primary objective is to estimate real-world vaccine effectiveness (VE) of COVID-19 vaccines against SARS-CoV-2 infection in the Netherlands, overall and in four subpopulations defined by age and medical risk.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The cohort consists of 45 547 community-dwelling participants aged 18-85 years who were included irrespective of their COVID-19 vaccination status or intention to get vaccinated. A medical risk condition is present in 4289 (19.8%) of 21 679 individuals aged 18-59 years, and in 9135 (38.3%) of 23 821 individuals aged 60-85 years. After 1 year of follow-up, 5502 participants had dropped out of the study. At inclusion and several times after inclusion, participants are asked to take a self-collected fingerprick blood sample in which nucleoprotein and spike protein receptor binding domain-specific antibody concentrations are assessed. Participants are also asked to complete monthly digital questionnaires in the first year, and 3 monthly in years 2-5, including questions on sociodemographic factors, health status, COVID-19 vaccination, SARS-CoV-2-related symptoms and testing results, and behavioural responses to COVID-19 measures.</AbstractText><AbstractText Label="FINDINGS TO DATE" NlmCategory="RESULTS">VASCO data have been used to describe VE against SARS-CoV-2 infection of primary vaccination, first and second booster and bivalent boosters, the impact of hybrid immunity on SARS-CoV-2 infection and VE against infectiousness. Furthermore, data were used to describe antibody response following vaccination and breakthrough infections and to investigate the relation between antibody response and reactogenicity.</AbstractText><AbstractText Label="FUTURE PLANS" NlmCategory="UNASSIGNED">VASCO will be able to contribute to policy decision-making regarding future COVID-19 vaccination. Furthermore, VASCO provides an infrastructure to conduct further studies and to respond to changes in vaccination campaigns and testing policy, and new virus variants.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER" NlmCategory="BACKGROUND">NL9279.</AbstractText><CopyrightInformation>© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huiberts</LastName><ForeName>Anne J</ForeName><Initials>AJ</Initials><Identifier Source="ORCID">0000-0003-3206-9777</Identifier><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoeve</LastName><ForeName>Christina E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kooijman</LastName><ForeName>Marjolein N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Melker</LastName><ForeName>Hester E</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hahné</LastName><ForeName>Susan Jm</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grobbee</LastName><ForeName>Diederick E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Binnendijk</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>den Hartog</LastName><ForeName>Gerco</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Wijgert</LastName><ForeName>Janneke Hhm</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-2728-4560</Identifier><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (UMCU), Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Hof</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knol</LastName><ForeName>Mirjam J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands mirjam.knol@rivm.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087507" MajorTopicYN="Y">Vaccine Efficacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 Infection</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>22</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39401962</ArticleId><ArticleId IdType="pmc">PMC11474871</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2024-085388</ArticleId><ArticleId IdType="pii">bmjopen-2024-085388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  Coronavirus disease (COVID-19) outbreak - about the virus 2020. 2022. https://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/novel-coronavirus-2019-ncov Available.</Citation></Reference><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383:2603–15. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: Moderna vaccine is nearly 95% effective, trial involving high risk and elderly people shows. BMJ. 2020;371:m4471. doi: 10.1136/bmj.m4471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m4471</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397:72–4. doi: 10.1016/S0140-6736(20)32623-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32623-4</ArticleId><ArticleId IdType="pmc">PMC7832220</ArticleId><ArticleId IdType="pubmed">33306990</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SJ, Moreira ED, Jr, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021;385:1761–73. doi: 10.1056/NEJMoa2110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Valk A, van Meijeren D, Smorenburg N, et al. Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2022. Vaccinatiegraad COVID-19 vaccinatie Nederland, 2021. COVID-19 vaccination coverage in the Netherlands in 2021.</Citation></Reference><Reference><Citation>Pluijmaekers A, de Melker H. Rijksinstituut voor Volksgezondheid en Milieu RIVM; 2022. The national immunisation programme in the Netherlands. Surveillance and developments in 2021-2022. Het Rijksvaccinatieprogramma in Nederland Surveillance en ontwikkelingen in 2021-2022.</Citation></Reference><Reference><Citation>Hahné S, Bollaerts K, Farrington P. Vaccination programmes: epidemiology, monitoring, evaluation. 1st. Routledge; 2021. edn.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control . Stockholm: ECDC; 2022. Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 50 years and older, ECDC multi-country study – first update.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control . Stockholm: ECDC; 2021. Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARSCoV-2, version 1.0.</Citation></Reference><Reference><Citation>World Health Organization . WHO; 2021. Evaluation of COVID-19 vaccine effectiveness - interim guidance.</Citation></Reference><Reference><Citation>Rijksinstituut voor Volksgezondheid en Milieu  Monitor Vaccinatiegraad Nationaal Programma Grieppreventie. 2022. https://www.rivm.nl/documenten/monitor-vaccinatiegraad-npg-2020 Available.</Citation></Reference><Reference><Citation>Rijksinstituut voor Volksgezondheid en Milieu  Role of RIVM in the COVID-19 vaccination. 2022. https://www.rivm.nl/en/covid-19-vaccination/role-of-rivm Available.</Citation></Reference><Reference><Citation>den Hartog G, Andeweg SP, Hoeve CE, et al. Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein. Sci Rep. 2023;13:18394. doi: 10.1038/s41598-023-45718-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-45718-8</ArticleId><ArticleId IdType="pmc">PMC10603038</ArticleId><ArticleId IdType="pubmed">37884642</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Netherlands  Bevolking; Kerncijfers. 2022. https://opendata.cbs.nl/statline/#/CBS/nl/dataset/37296ned/table?ts=1641215234687 Available.</Citation></Reference><Reference><Citation>Onderwijs | De sociale staat van Nederland: 2020; 2022. Sociaal en Cultureel Planbureau.https://digitaal.scp.nl/ssn2020/onderwijs Available.</Citation></Reference><Reference><Citation>Pijpers J, van Roon A, van Roekel C, et al. Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study. Vaccines. 2023;11:1409. doi: 10.3390/vaccines11091409.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11091409</ArticleId><ArticleId IdType="pmc">PMC10537724</ArticleId><ArticleId IdType="pubmed">37766087</ArticleId></ArticleIdList></Reference><Reference><Citation>Huiberts AJ, de Gier B, Hoeve CE, et al. Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study. Int J Infect Dis. 2023;133:36–42. doi: 10.1016/j.ijid.2023.04.401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.04.401</ArticleId><ArticleId IdType="pmc">PMC10118053</ArticleId><ArticleId IdType="pubmed">37086863</ArticleId></ArticleIdList></Reference><Reference><Citation>Huiberts AJ, de Gier B, Hoeve CE, et al. Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022. Euro Surveill. 2023;28:2300087. doi: 10.2807/1560-7917.ES.2023.28.7.2300087.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2023.28.7.2300087</ArticleId><ArticleId IdType="pmc">PMC9936593</ArticleId><ArticleId IdType="pubmed">36795500</ArticleId></ArticleIdList></Reference><Reference><Citation>de Gier B, Huiberts AJ, Hoeve CE, et al. Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology. Nat Commun. 2023;14:4793. doi: 10.1038/s41467-023-40195-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40195-z</ArticleId><ArticleId IdType="pmc">PMC10412579</ArticleId><ArticleId IdType="pubmed">37558656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeve CE, Huiberts AJ, de Gier B, et al. COVID-19 vaccination-induced antibody responses and waning by age and comorbidity status in a large population-based prospective cohort study. Vaccine (Auckl) 2024;42:126121. doi: 10.1016/j.vaccine.2024.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.07.022</ArticleId><ArticleId IdType="pubmed">38997851</ArticleId></ArticleIdList></Reference><Reference><Citation>Holwerda MR, Hoeve CE, Huiberts AJ, et al. Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands. Euro Surveill. 2021;29 doi: 10.2807/1560-7917.ES.2024.29.25.2300585.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.25.2300585</ArticleId><ArticleId IdType="pmc">PMC11191418</ArticleId><ArticleId IdType="pubmed">38904110</ArticleId></ArticleIdList></Reference><Reference><Citation>Vercoulen J, Alberts M, Bleijenberg G. De checklist individual strength (CIS) Gedragsther. 1999;32:131–6.</Citation></Reference><Reference><Citation>Worm-Smeitink M, Gielissen M, Bloot L, et al. The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. J Psychosom Res. 2017;98:40–6. doi: 10.1016/j.jpsychores.2017.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2017.05.007</ArticleId><ArticleId IdType="pubmed">28554371</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Lynn George M, Kakouras I, et al. Reliability, Validity, and Responsiveness of the Short Form 12-Item Survey (SF-12) in Patients With Back Pain. Spine (Phila Pa 1986) 2003;28:1739–45. doi: 10.1097/01.BRS.0000083169.58671.96.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BRS.0000083169.58671.96</ArticleId><ArticleId IdType="pubmed">12897502</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>